ACXP vs. DARE, VIRX, THTX, NRXP, ENLV, SPRB, IPA, APRE, FBIO, and ACST
Should you be buying Acurx Pharmaceuticals stock or one of its competitors? The main competitors of Acurx Pharmaceuticals include Daré Bioscience (DARE), Viracta Therapeutics (VIRX), Theratechnologies (THTX), NRx Pharmaceuticals (NRXP), Enlivex Therapeutics (ENLV), Spruce Biosciences (SPRB), ImmunoPrecise Antibodies (IPA), Aprea Therapeutics (APRE), Fortress Biotech (FBIO), and Acasti Pharma (ACST). These companies are all part of the "pharmaceutical preparations" industry.
Acurx Pharmaceuticals (NASDAQ:ACXP) and Daré Bioscience (NASDAQ:DARE) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, community ranking, valuation, media sentiment, earnings and analyst recommendations.
Daré Bioscience received 342 more outperform votes than Acurx Pharmaceuticals when rated by MarketBeat users. However, 90.91% of users gave Acurx Pharmaceuticals an outperform vote while only 73.18% of users gave Daré Bioscience an outperform vote.
In the previous week, Daré Bioscience had 3 more articles in the media than Acurx Pharmaceuticals. MarketBeat recorded 6 mentions for Daré Bioscience and 3 mentions for Acurx Pharmaceuticals. Acurx Pharmaceuticals' average media sentiment score of 0.47 beat Daré Bioscience's score of 0.17 indicating that Acurx Pharmaceuticals is being referred to more favorably in the media.
Acurx Pharmaceuticals has higher earnings, but lower revenue than Daré Bioscience. Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than Daré Bioscience, indicating that it is currently the more affordable of the two stocks.
Acurx Pharmaceuticals currently has a consensus target price of $12.00, suggesting a potential upside of 494.06%. Daré Bioscience has a consensus target price of $6.00, suggesting a potential upside of 1,780.29%. Given Daré Bioscience's higher possible upside, analysts clearly believe Daré Bioscience is more favorable than Acurx Pharmaceuticals.
Acurx Pharmaceuticals' return on equity of -289.69% beat Daré Bioscience's return on equity.
11.5% of Acurx Pharmaceuticals shares are held by institutional investors. Comparatively, 6.7% of Daré Bioscience shares are held by institutional investors. 35.3% of Acurx Pharmaceuticals shares are held by insiders. Comparatively, 5.3% of Daré Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Acurx Pharmaceuticals has a beta of -1.79, meaning that its share price is 279% less volatile than the S&P 500. Comparatively, Daré Bioscience has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500.
Summary
Daré Bioscience beats Acurx Pharmaceuticals on 8 of the 15 factors compared between the two stocks.
Get Acurx Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACXP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Acurx Pharmaceuticals Competitors List
Related Companies and Tools
